scholarly journals Modified Radical Mastectomy for Male Breast Cancer

2019 ◽  
Vol 20 ◽  
pp. 1336-1339
Author(s):  
Mahmoud Musa Al Awayshih ◽  
Mohammad Nabih Nofal ◽  
Ali Jad Yousef
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Modified Radical Mastectomy

scholarly journals Management and Outcomes of Male Breast Cancer in Zaria, Nigeria

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Adamu Ahmed ◽  
Yahaya Ukwenya ◽  
Adamu Abdullahi ◽  
Iliyasu Muhammad
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Advanced Disease ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Tumor Diameter ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Modified Radical Mastectomy ◽  
Male Patients

Male breast cancer is an uncommon disease accounting for only 1% of all breast cancers. We present the evaluation, treatment and outcome of male patients seen with breast cancer in our institution. Male patients that had histological diagnosis of breast cancer from 2001 to 2010 were retrospectively evaluated. After evaluation patients were treated with modified radical mastectomy. Combination chemotherapy was given to patients with positive axillary lymph nodes. Radiotherapy and hormonal therapy were also employed. There were 57 male patients with breast cancer which accounted for 9% of all breast cancers seen during the study period. Their mean age was 59 ± 2.3 years. The mean tumor diameter was 13 ± 2.5 cm. Fifty three (93%) patients presented with advanced disease including 15 with distant metastasis. Four patients with stage II disease were treated with modified radical mastectomy, chemotherapy and tamoxifen. Of the 30 patients with sage III disease that had modified radical mastectomy, complete axillary clearance and tumor free margins were achieved in 25. Overall 21 (36.8%) patients were tumor free at one year. Overall 5-year survival was 22.8%. In conclusion, male patients with breast cancer present with advanced disease which is associated with poor outcome of treatment.

scholarly journals Male occult triple-negative breast cancer

2019 ◽  
Vol 12 (4) ◽  
pp. e229482
Author(s):  
Basma Alsayed ◽  
Hussain Adnan Abdulla ◽  
Hadi Alaskar ◽  
Ali Dhaif
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Breast Lesion ◽  
Triple Negative ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Modified Radical Mastectomy ◽  
Important Condition ◽  
Axillary Metastases ◽  
Rare Type

Male breast cancer is a rare but important condition accounting for only 1% of breast cancer worldwide and less than 1% of all male malignancies. Occult male breast cancer is an extremely rare type of male breast cancer that manifests as axillary metastases without an identifiable breast lesion. We report a case of triple-negative occult male breast cancer who underwent modified radical mastectomy.

scholarly journals Rare Case of Male Breast Cancer and Axillary Lymphoma in the Same Patient: An Unique Case Report

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Emiliano Sordi ◽  
Katia Cagossi ◽  
Maria Grazia Lazzaretti ◽  
Daniel Gusolfino ◽  
Fabrizio Artioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Malignant Lesion ◽  
Gene Mutations ◽  
Radical Mastectomy ◽  
Simultaneous Presentation ◽  
Needle Aspiration ◽  
Male Breast ◽  
First Case

Breast cancer in men is uncommon, and even more rare is the simultaneous presentation of two different malignancies. A 39-year-old man was diagnosed with both breast cancer and axillary lymphoma. Familiar history revealed that his mother died because of breast cancer. The patient underwent fine needle aspiration leading to the diagnosis of malignant lesion. Modified radical mastectomy was performed. Histology revealed an infiltrating ductal carcinoma 2.8 cm wide, grade 2, with vascular and lymphatic invasion. Surprisingly, one of the second level nodes was confirmed as a high-grade large B cell non-Hodgkin's lymphoma. No family inheritance or gene mutations (BRCA 1 and 2) were found. The patient underwent local radiotherapy, followed by 6 chemotherapy courses (RCHOP) and treatment with tamoxifen 20 mg/daily. To our knowledge, this is the first case reported in literature of male breast cancer and axillary lymphoma simultaneously confirmed in the same patient.

Retrospective analysis on patients with male breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19681-19681
Author(s):  
A. M. Alvarez ◽  
M. N. Gandur Quiroga ◽  
G. Cinat ◽  
J. Iturbe ◽  
T. Said Nissi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
History Of ◽  
The Media ◽  
Histological Characteristics ◽  
Breast Lumps

19681 Background: Male breast cancer is uncommon, 1%(0.7 %)of all breast cancer. Nevertheless, the incidence has climbed 26% over the past 25 years. Objetive: Analyze the form of presentation and clinical evolution of patients with male breast cancer studied from 1977 to 2005. Methods: From 1977 to 2005 53 charts were analyzed: age, clinical presentation, stage (st), histological characteristics and nodal involvement. Results: Age: 33 years to 83 years (median= 59 years). Mean durations of symptoms before presentations: 11 months (m) (range 1 - 84 m.) . Forty-six (86.7%) patients (pts) had history of breast lumps, 9 (17%) were painful. Skin involvement and ulceration were present in 5 (9.43%) and 4 (7.54 %) respectively. One case of bilateralism was found. Seven (13.2%) st. I; 18 (33.96%) st. II; 20 (37.73%) st. III and 7 (13.2%) st. IV. Radical mastectomy was done in 41 pts (77.35%). Invasive ductal carcinoma was the most common histological type in 45 (84.9%). One case of lobular carcinoma was found. 60.4% of tumours expressed hormonal receptor. Adyuvant treatment: Adriamycin-based chemotherapy in 20 pts and CMF in 8 pts. Hormonotherapy was offered in 10 (19%) pts of the previous group, radiotherapy to 12 pts. twenthy pts (37.73%) presented recurrence; most common was bone in 10. The st. I and II estimated 5-year survival rate was 68% IC 95% (44–84%), st. III was 44% IC 95% (23 - 67%), st. IV (median = 24 m) with range (16 - 56 m). The 72% IC 95% (48–88%) patients st. I and II was free of disease at the 5-years, st. III was free 24% IC 95% (9–49%), st. IV (median = 7,5 m) with range (7–14 m). Conclusions: The media age at diagnosis was 59 years (10 years less than the international bibliography). (IB). Our group had longer time to presentation: 11 vs. 6 m., (IB) and most of them where in st. III. Hormonal receptore were positive in 60%. No significant financial relationships to disclose.

scholarly journals Male breast cancer – how to treat?

2007 ◽  
Vol 10 (8) ◽  
Author(s):  
E. D. Rossmann ◽  
A. Liljegren ◽  
J. Bergh
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Radical Mastectomy ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Aggressive Disease ◽  
Metastatic Setting ◽  
Her 2 ◽  
Low Incidence ◽  
Multimodal Management

AbstractTreatment principles of breast cancer in males are derived from studies performed among females, while the low incidence in males has so far precluded such studies. The therapy recommendations for males therefore lack the solid evidence, frequently present for females with breast cancer. The primary breast cancer diagnosis in males is not infrequently in stage III/IV and at higher age, thereby requiring multiprofessional and multimodal management including preoperative therapy and adjuvant therapies based on the tumour’s biological characteristics and the clinical circumstances. The majority of male breast cancer tumours are oestrogen-receptor positive and adjuvant/neoadjuvant tamoxifen is therefore recommended, surgery is frequently radical mastectomy and adjuvant radiotherapy should likely be used on wider indications. Chemotherapy should be considered both in the adjuvant and metastatic setting for receptor-negative cancers and for patients with biologically aggressive disease. Trastuzumab should be offered to patients with Her-2/neu-positive disease, while the use of aromatase inhibitors is more uncertain due to differences in the hormonal environment in males.

scholarly journals Survival Outcomes in Male Breast Cancer – A Single Institution Experience

2018 ◽  
Vol 3 (4) ◽  
pp. 71
Author(s):  
Nisha Hariharan
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Treatment Guidelines ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Survival Outcomes ◽  
Breast Cancers ◽  
Breast Cancer Patients

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.  

Male breast cancer retrospective institution review of a 17-year period

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11638-e11638
Author(s):  
C. Rodriguez Franco ◽  
D. Aguiar Bujanda ◽  
S. Saura Grau ◽  
U. Bohn Sarmiento ◽  
J. Aguiar Morales
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Good Survival ◽  
Histologic Subtype ◽  
History Of

e11638 Background: Male breast cancer (MBC) is a very uncommon illness relative to female breast cancer (FBC) The are some differences between both that could influence the management, like gene expression, hormonal enviroment and anatomy of the gland. Methods: Retrospective review of patients diagnosed in a seventeen year period (1990–2007). Results: There were 22 male patients diagnosed in our institution with a median age of 62.4 years (range 34 to 83 years) during the period. One had bilateral breast cancer. Stage of disease was I-II in 13 patients (59%), III in 8 patients (36%), and IV in 1 patient (5%). Five patients (22.7%) had familiar history of breast cancer and 3 patients (13%) had familiar history of other kind of neoplasias. Hormonal receptor were positive in thirteen patiens (59%) and 5 were unknown (23%). Ductal carcinoma was the predominant histologic subtype with 17 patients (77%). Other types were pleomorfic, mucoid and papilar carcinoma (one each type) and 3 patients with intrapapilar carcinoma with microinfiltration. Eleven of 20 patologic available axilla had node positive (55%). Grade were I in 3 patients (13%), II in 4 patients (18%), III in 8 (37%) and undefined in in 7 (32%). Surgery was the initial treatment in 18 patients (81%), just 2 of them performing tumorectomy and the other 16 radical mastectomy. 3 patients receive neoadyuvant chemotherapy with 1 complete response and one partial response. 13 patients (59%) received adjuvant radiotherapy (RT) and 17 (77%) adjuvant hormonal therapy (HT) mostly of them with tamoxifen (14/17) and the others 3 patients with aromatase inhibitors. Adjuvant chemotherapy was used in 9 (41%) patients with an antracycline regimen. With a median follow-up of 78 months (range 7–125), overall survival was 77 % with 3 patients died with progression disease and two patients died because of intercurrent illness without evidence of cancer progression. Regarding to our population area we had an incidence of 0.96/100.000 inhabitants during this 17 year period. Conclusions: MBC in our area are in the upper limit of occidental countries incidence. Most cases can be treated with radical intention with surgery (mostly radical) and adjuvant treatment with a good survival percentage. We manage MBC like we do FBC because of absence of clinical randomized trial specific for MBC. No significant financial relationships to disclose.

Changes in Male Breast Cancer over a 30-Year Period

2008 ◽  
Vol 74 (8) ◽  
pp. 707-712 ◽  
Author(s):  
Nicholas Paul Schaub ◽  
Nell Maloney ◽  
Heather Schneider ◽  
Eric Feliberti ◽  
Roger Perry
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Retrospective Chart Review ◽  
Male Breast ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Lymph Node Mapping ◽  
Presenting Symptoms

Male breast cancer is a rare clinical entity accounting for approximately 1 per cent of all breast cancers. The present study investigated changes in patient characteristics, disease patterns, treatment, and outcomes over a 30-year period. A retrospective chart review was performed on male breast cancer patients treated between 1975 and 2005 at Eastern Virginia Medical School, Norfolk, VA. Demographic, pathologic, treatment, and survival information was collected. To facilitate comparison of trends, the patients were divided into two groups: Cohort A (1972–1991, previously reported) and Cohort B (1992–2005). Both cohorts included 28 male patients. Comparing the cohorts, no statistical differences were noted in median age, ethnicity, presenting symptoms, or progesterone receptor status. In Cohort A, 70 per cent of patients were estrogen receptor positive, compared with 100 per cent of Cohort B ( P = 0.02). Her2/neu was positive in three of five patients in Cohort B. There was a trend toward more conservative surgery, with no radical mastectomy or orchiectomy performed in Cohort B. Only two patients had sentinel lymph node mapping, both from Cohort B. Infiltrating ductal carcinoma was more prevalent in Cohort B ( P = 0.04). For Cohort A and B, 5-year survival was 43 per cent and 51 per cent, respectively, which was not statistically significant. For male breast cancer, radical mastectomy is no longer a common treatment modality. Male breast cancer of today is more hormonally responsive which may have important implications for therapy. Survival has not significantly improved over the previous 30 years. Compilation of multi-institutional data of male breast cancer is needed to advance the treatment of this uncommon disease.

Sign in / Sign up

Export Citation Format

Share Document